|
Baseline:
|
158 (100%) Assigned to snus
|
161 (100%) Assigned to placebo
|
| |
158 (100%) Received assigned product, included in efficacy and safety analyses
|
161 (100%) Received assigned product, included in efficacy and safety analyses
|
|
Week 1-24:
|
26 (16%) Discontinued study
|
23 (14%) Discontinued study
|
| |
132 (84%) Completed protocol follow-up
|
138 (86%) Completed protocol follow-up
|
|
Week 24 visit:
|
31 (20%) Failed to achieve protocol definition of smoking reduction
|
29 (18%) Failed to achieve protocol definition of smoking reduction
|
| |
101 (64%) Continued in the study
|
109 (68%) Continued in the study
|
|
Week 24-48:
|
13 (8%) Discontinued study
|
8 (5%) Discontinued study
|
| |
88 (56%) Completed protocol follow-up
|
101 (63%) Completed protocol follow-up
|
